Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372617 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL17372406 | 0.81 | CYP1A2 (0.49) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL2346676 | 0.71 | MKNK1 (0.41) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL5566830 | 0.69 | SMN1; SMN2 (0.38) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL546926 | 0.68 | NPC1 (0.37) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL545883 | 0.67 | NPC1 (0.38) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL17260458 | 0.66 | SYK (0.47) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL7264355 | 0.64 | BRD4 (0.67) | BRD4HTTAURKABTK | |
| SCHEMBL5860314 | 0.62 | POLB (0.45) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL5858886 | 0.62 | BRD4 (0.42) | SMN1; SMN2BRD4HSD17B10BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11015194-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669544-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20050164235-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue; drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs for hepatitis virus | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | ALNYLAM PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005004794-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | SMN1; SMN2 1418/4885BRD4 2344/4885TP53 707/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885BRD4 2420/4885TP53 1516/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | SMN1; SMN2 715/4885BRD4 1458/4885TP53 171/4885 |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | SMN1; SMN2 688/4885BRD4 2426/4885TP53 180/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | SMN1; SMN2 179/4885BRD4 2399/4885TP53 42/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | SMN1; SMN2 2665/4885BRD4 2420/4885TP53 1516/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | SMN1; SMN2 179/4885BRD4 2399/4885TP53 42/4885 |
| US-10669544-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | SMN1; SMN2 179/4885BRD4 2399/4885TP53 42/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | SMN1; SMN2 2749/4885BRD4 3742/4885TP53 1234/4885 |
| US-20050164235-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue; drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs for hepatitis virus | HAVCR2, LDLR, RNASE1 | SMN1; SMN2 3753/4885BRD4 3730/4885TP53 1008/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | SMN1; SMN2 700/4885BRD4 2420/4885TP53 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.